Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated. We evaluated the safety, tolerability, and efficac...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Abraham, Jame, Montero, Albert J., Jankowitz, Rachel C., Salkeni, Mohamad Adham, Beumer, Jan H., Kiesel, Brian F., Piette, Fanny, Adamson, Laura M., Nagy, Rebecca J., Lanman, Richard B., Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J., Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L., Lucas, Peter C., Jacobs, Samuel A.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2019
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784849/
https://ncbi.nlm.nih.gov/pubmed/31442103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00858
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker